glp 1 drugs and kidney function Current GLP-1 receptor agonists recommendations in patients with TrimRX | Custom GLP-1 Dosing

95% CI 0.3, 1.7) or thyroid malignancies (RR 1.4

The research examined patient data from more than 142,000 people with type 2 diabetes (T2DM) or obesity

author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law

Although this difference approached but did not reach the threshold for clinical significance established in other studies,134 the findings suggest the potential neuroprotective effects of lixisenatide, possibly mediated by increased synaptic dopamine levels, as supported by preclinical and clinical research in addictive disorders.135,136 Further investigations are warranted to elucidate the mechanisms underlying GLP-1RAs action in PD

doi:10.1016/j.tem.2020.02.006 Nauck MA, Meier JJ

Wang XH, Li L, Hlscher C, Pan YF, Chen XR, Qi JS